Slaughter and May is advising Hikma Pharmaceuticals PLC (Hikma) in relation to its acquisition of Medlac Pharma Italy, Co. Ltd. (Medlac), an injectable manufacturing company in Vietnam. The acquisition includes a high-quality injectable facility, adjacent vacant land, Medlac’s product portfolio of 23 injectable products, its pipeline and all employees.

The acquisition was announced on 7 November 2018.

Hikma is a leading manufacturer of generic injectables in the US and has a growing presence in Europe and MENA. This acquisition provides Hikma with a foothold in Vietnam, one of the most dynamic emerging markets in Asia. Driven by a growing population, government healthcare reforms and strong economic development, Vietnam has been the fastest growing pharmaceutical market in South East Asia in recent years and this fast-paced growth is expected to continue.

Slaughter and May supported Hikma’s internal legal team and worked closely with Anne Terrasse.
Contacts

Chris McGaffin (partner), Eilene Teh (associate)